FEVAXYN QUATRIFEL SUSPENSION FOR INJECTION FOR CATS

Country: Ireland

Language: English

Source: HPRA (Health Products Regulatory Authority)

Active ingredient:

FELINE PANLEUKOPENIA VIRUS (CU4 VIRUS STRAIN) INACTIVATED, FELINE CALCIVIRUS (255 VIRUS STRAIN) INACTIVATED, FELINE RHINOTRACHEITIS VIRUS (605 VIRUS STRAIN) INACTIVATED, CHLAMYDOPHILA FELIS (INACTIVATED) (CELLO STRAIN)

Available from:

Zoetis Ireland Limited

ATC code:

QI06AL02

INN (International Name):

FELINE PANLEUKOPENIA VIRUS (CU4 VIRUS STRAIN) INACTIVATED, FELINE CALCIVIRUS (255 VIRUS STRAIN) INACTIVATED, FELINE RHINOTRACHEI

Dosage:

Unknown

Pharmaceutical form:

Suspension for Injection

Prescription type:

POM

Therapeutic group:

Feline

Therapeutic area:

Inactivated Feline panleucopenia virus / parvovirus vaccine + inactivated Feline rhinotracheitis vi

Therapeutic indications:

Immunological - Inactivated vaccine

Authorization status:

Authorised

Authorization date:

2013-11-04

Summary of Product characteristics

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Fevaxyn Quatrifel Suspension for injection for cats
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
*
R.P.= Relative Potency (by in-vitro assay)
3 PHARMACEUTICAL FORM
Suspension for injection.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Cats from 8 weeks of age.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the active immunisation of healthy cats 8 weeks or older to reduce clinical symptoms of disease caused by Feline
Panleucopenia infection and to reduce clinical symptoms of respiratory diseases caused by Feline Rhinotracheitis virus,
Feline Calicivirus and _Chlamydophila felis_.
Onset of immunity is from 2 weeks after completion of the primary vaccination course.
The duration of immunity lasts up to at least one year following the primary vaccination course.
4.3 CONTRAINDICATIONS
None known.
Per dose of 1ml:
ACTIVE SUBSTANCES
Relative Potency (R.P.)*
Inactivated feline panleucopenia virus, strain CU4 8.50 - 12.25
Inactivated feline calicivirus, strain 255
1.26 - 2.40
Inactivated feline rhinotracheitis virus, strain 605 1.39 - 2.10
Inactivated _Chlamydophila felis, _strain Cello
1.69 - 3.50
ADJUVANT
Ethylene/maleic anhydride (EMA)
1% (v/v)
Neocryl
3% (v/v)
Emulsigen SA
5% (v/v)
EXCIPIENTS:
For the full list of excipients see section 6.1.
HEALTH PRODUCTS REGULATORY AUTHORITY
________________________________________________________________________________________________________________________
_Date Printed 23/07/2015_
_CRN 7021392_
_page number: 1_
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
4.5 SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
Should an allergic reaction occur for any reason, intra-muscular adrenaline should be administered.
In any animal population, a small number of individuals may fail to re